Industry

Amgen’s Repatha® cuts risk of first major adverse cardiovascular events by 25%...

Repatha is the First and Only PCSK9 Inhibitor to Significantly Reduce the Risk of First Heart Attack and Stroke. Continue Reading

Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG)...

Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions. Continue Reading

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I...

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations Continue Reading

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C..

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 CORALreef Lipids trial demonstrating that treatment with enlicitide decanoate, an investigational, once-daily oral... Continue Reading

Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans

Medicare beneficiaries with obesity or overweight will have access to Zepbound and orforglipron, if approved, at $50 a month Continue Reading

BridgeBio to Present ATTR-CM and V142I (V122I) Data from ATTRibute-CM at AHA 2025

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that ten moderated digital posters will be shared at the American Heart Association (AHA) Scientific Sessions 2025, taking place in New Orleans. Continue Reading

HeartFlow launches PCI Navigator to support smarter, data-driven PCI planning

New Heartflow PCI Navigator to Equip Interventional Cardiologists with Pre-procedural Insights to Enable PCI Planning Continue Reading

Landmark phase 3 trial (VESALIUS-CV) meets primary endpoints in a cardiovascular primary prevention

Adding Repatha to Standard Therapy of Statins or Other LDL-C Lowering Treatments Significantly Reduces Cardiovascular Events Compared with Standard Therapy Alone Repatha is Now the First and Only PCSK9 Inhibitor to Demonstrate Significant Reduction of Cardiovascular Events Continue Reading

Evkeeza® (evinacumab-dgnb) now FDA-approved for children ≥1 year with ultra-rare high cholesterol

FDA approval extends the indication of Evkeeza to treat younger patients with homozygous hypercholesterolemia (HoFH) HoFH is an inherited condition characterized by extremely high levels of low-density lipoprotein cholesterol (LDL-C) Continue Reading

Lexicon submits new data to FDA supporting Zynquista® benefit-risk in type 1 diabetes

Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes Continue Reading

Merck’s oral PCSK9 inhibitor enlicitide hits all endpoints in pivotal CORALreef Lipids trial

Merck’s Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Met All Primary and Key Secondary Endpoints in Adults with Hypercholesterolemia in Pivotal CORALreef Lipids Study Continue Reading

Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory

INDIANAPOLIS, Aug. 26, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ATTAIN-2 trial, evaluating orforglipron, an investigational oral GLP-1 receptor agonist, in adults with obesity or overweight and type 2 diabetes. In the trial,... Continue Reading